SC 13G 1 cvrx_sch13g-123122.htm SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1- Exit Filing)*

CVRx, Inc.

(Name of Issuer)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

December 31, 2022

126638 10 5

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number.

13G/A1

CUSIP No. 126638 10 5

1. Names of Reporting Persons.

GSK plc

2. Check the Appropriate Box if a Member of a Group

(a) o

(b) o

3. SEC Use Only

4. Citizenship or Place of Organization

England and Wales

   Number of Shares
   Beneficially
   Owned by
   Each Reporting
   Person With:

5. Sole Voting Power

1,007,583

6. Shared Voting Power

7. Sole Dispositive Power

1,007,583

8. Shared Dispositive Power

9. Aggregate Amount Beneficially Owned by Each Reporting Person

1,007,583 ⁽¹⁾

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares o

11. Percent of Class Represented by Amount in Row (9)

4.9 % ⁽²⁾

12. Type of Reporting Person

⁽¹⁾	Common Stock (as defined below) are held of record by Action Potential Venture Capital Limited and Glaxo Group Limited, each of which is an indirect, wholly-owned subsidiary of the Reporting Person.

⁽²⁾	Based upon 20,584,163 shares of Common Stock outstanding as of October 28, 2022, as reported in the Issuer’s Form 10-Q furnished with the Securities and Exchange Commission (the “SEC”) on November 4, 2022.

13G/A1

CUSIP No. 126638 10 5

ITEM 1.

(a)

Name of Issuer:

CVRx, Inc. (the “Company”)

(b)

Address of Issuer's Principal Executive Offices:

9201 West

Broadway Avenue

Suite 650

Minneapolis

MN 55445

ITEM 2.

(a)

Name of Person Filing:

GSK plc.

(b)

Address of Principal Business Office, or if None, Residence:

980 Great West Road

Brentford

Middlesex

TW8 9GS

England

(c)

Citizenship:

England and Wales

(d)

Title of Class of Securities:

Common Stock, par value $0.01 (the “Common Stock”)

(e)

CUSIP Number:

126638 10 5

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

Not Applicable

ITEM 4. OWNERSHIP.

The information in items 1 and 5 through 11 on the cover page of this Schedule 13G is hereby incorporated by reference.

13G/A1

CUSIP No. 126638 10 5

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Not Applicable

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

Not Applicable

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not Applicable

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

Not Applicable

ITEM 10. CERTIFICATIONS.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

13G/A1

CUSIP No. 126638 10 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 6, 2023

(Date)

s/ Victoria A. Whyte

(Signature)

Victoria A. Whyte, Authorized Signatory

(Name/Title)

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.